Expression of epidermal growth factor receptor (EGFR) and downstream-activated peptides in surgically excised non-small-cell lung cancer (NSCLC).

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Lung Cancer

• Publication date

  2003-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0169-5002(03)00225-3PMID 12871775
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Pursuit of Optimal Outcomes in Cancer Therapy in a New Age of Rationally Designed Target-Based Anticancer Agents

  2012cited by this paper
• Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients

  2002cited by this paper
• Phosphorylation of ERK1/2 mitogen‐activated protein kinase is associated with poor response to anti‐hormonal therapy and decreased patient survival in clinical breast cancer

  2001cited by this paper
• The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy.

  2001cited by this paper
• Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.

  2001cited by this paper
• Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation.

  2001cited by this paper
• Epidermal growth factor (EGF) suppresses staurosporine-induced apoptosis by inducing mcl-1 via the mitogen-activated protein kinase pathway

  2000cited by this paper
• Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression.

  2000cited by this paper
• Interrelationships between Cellular Nucleotide Excision Repair, Cisplatin Cytotoxicity, HER‐2/neu Gene Expression, and Epidermal Growth Factor Receptor Level in Non‐small Cell Lung Cancer Cells

  2000cited by this paper
• ErbB‐2 kinase is required for constitutive stat 3 activation in malignant human lung epithelial cells

  1999cited by this paper
• A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers.

  1999cited by this paper
• Activation of mitogen-activated protein kinase associated with prostate cancer progression.

  1999cited by this paper
• Epidermal Growth Factor Protects Epithelial Cells against Fas-induced Apoptosis

  1999cited by this paper
• Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients.

  1998cited by this paper
• Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival.

  1998cited by this paper
• Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas.

  1998cited by this paper
• Herceptin raises its sights beyond advanced breast cancer.

  1998cited by this paper
• Expression in lung carcinomas of platelet-derived growth factor and its receptors.

  1997cited by this paper
• Basic fibroblast growth factor and vascular fibroblast growth factor measured in sera from patients with non-small cell lung cancer.

  1997cited by this paper
• Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research

  1995cited by this paper
• TNM supplement 1993. A commentary on uniform use

  1994cited by this paper
• Expression and function of the insulin‐like growth factor I system in human non‐small‐cell lung cancer and normal lung cell lines

  1994cited by this paper
• The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival.

  1993cited by this paper
• Immunohistochemical study of glutathione‐related enzymes and proliferative antigens in lung cancer. Relation to cisplatin sensitivity

  1993cited by this paper
• Expression of epidermal growth factor receptor (EGF-R) in non-small cell lung cancer. Use of archival tissue and correlation of EGF-R with histology, tumour size, node status and survival.

  1989cited by this paper
• International Histological Classification of Tumours

  1981cited by this paper
• Evaluation of survival data and two new rank order statistics arising in its consideration.

  1966cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Potential of Natural Products in the Treatment of Glioma: Focus on Molecular Mechanisms

  2024cites this paper
• PRMT5-mediated methylation of STAT3 is required for lung cancer stem cell maintenance and tumour growth

  2024cites this paper
• Bazedoxifene Inhibits Cell Viability, Colony‐Forming Activity, and Cell Migration in Human Non–Small Cell Lung Cancer Cells and Improves the Treatment Efficacy of Paclitaxel and Gemcitabine

  2024cites this paper
• NSCLC presents metabolic heterogeneity, and there is still some leeway for EGF stimuli in EGFR-mutated NSCLC.

  2023cites this paper
• Glucose metabolism involved in PD-L1-mediated immune escape in the malignant kidney tumour microenvironment

  2021cites this paper
• Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design

  2021cites this paper
• Targeting STAT3 signaling pathway in cancer by agents derived from Mother Nature.

  2020cites this paper
• Thrombin is a therapeutic target for non-small-cell lung cancer to inhibit vasculogenic mimicry formation

  2020cites this paper
• Cytotoxicity, in silico predictions and molecular studies for androstane heterocycle compounds revealed potential antitumor agent against lung cancer cells

  2020cites this paper
• Rational design of EGFR dimerization-disrupting peptides: A new strategy to combat drug resistance in targeted lung cancer therapy.

  2020cites this paper
• Silencing AXL by covalent siRNA-gelatin-antibody nanoconjugate inactivates mTOR/EMT pathway and stimulates p53 for TKI sensitization in NSCLC.

  2019cites this paper
• Novel 1,4-dihydropyridine induces apoptosis in human cancer cells through overexpression of Sirtuin1

  2018cites this paper
• A Placebo‐Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First‐Line Treatment of Patients With Advanced Nonsquamous Non–Small‐Cell Lung Cancer and Systemic Inflammation

  2018cites this paper
• EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma

  2017cites this paper
• Novel Synthetic bisindolylmaleimide alkaloids inhibit STAT3 activation by binding to the SH2 domain and suppress breast xenograft tumor growth

  2017cites this paper
• Adenocarcinoma of the lung: an exploration of the relationships between histopathology, molecular pathology and inflammatory markers and their relationship to patient outcomes

  2017cites this paper
• Recent advances in understanding Cushing disease: resistance to glucocorticoid negative feedback and somatic USP8 mutations

  2017cites this paper
• Immunoexpression analysis of selected JAK/STAT pathway molecules in patients with non- small-cell lung cancer.

  2017cites this paper
• Curcumin inhibits human non-small cell lung cancer xenografts by targeting STAT3 pathway.

  2017cites this paper
• Correlation between p-STAT3 overexpression and prognosis in lung cancer: A systematic review and meta-analysis

  2017cites this paper
• SPECT imaging evaluation of 111indium‐chelated cetuximab for diagnosing EGFR‐positive tumor in an HCT‐15‐induced colorectal xenograft

  2017cites this paper
• Effect of Small Molecule Inhibitor Fisetin over Proliferation of Human Non-Small Cell Pulmonary Carcinoma

  2016cites this paper
• Targeting the Mammalian Target of Rapamycin in Lung Cancer☆

  2016cites this paper
• Analysis of the relationship between PM2.5 and lung cancer based on protein-protein interactions.

  2016cites this paper
• Association of Nuclear PIM1 Expression with Lymph Node Metastasis and Poor Prognosis in Patients with Lung Adenocarcinoma and Squamous Cell Carcinoma

  2016cites this paper
• Detection of microRNA-200b may predict the inhibitory effect of gefitinib on non-small cell lung cancer and its potential mechanism.

  2016cites this paper
• EGR 1 , EGFR and IGF 1 R protein expressions in non-small cell lung cancer and their clinical significances

  2016cites this paper
• Epidermal Growth Factor Receptor, Excision-Repair Cross-Complementation Group 1 Protein, and Thymidylate Synthase Expression in Penile Cancer.

  2016cites this paper
• ERK and AKT phosphorylation status in lung cancer and emphysema using nanocapillary isoelectric focusing

  2016cites this paper
• Resveratrol induces cell apoptosis in adipocytes via AMPK activation.

  2015cites this paper
• implications and potential prognostic and predictive biomarkers of the PI3K-Akt-mTOR signaling pathway. Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer

  2015cites this paper
• Role of Inflammation Amplifier-Induced Growth Factor Expression in the Development of Inflammatory Diseases.

  2015cites this paper
• Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer

  2015cites this paper
• Cell signaling regulatory mechanisms controlling epithelial-mesenchymal transition in carcinoma

  2015cites this paper
• Case Study: Modeling and Comparison of NSCLC and Normal EGFR Signaling

  2015cites this paper
• Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer.

  2015cites this paper
• Trends in the early investigational drug development and areas for improvement

  2015cites this paper
• Enoxaparin Sensitizes Human Non–Small-Cell Lung Carcinomas to Gefitinib by Inhibiting DOCK1 Expression, Vimentin Phosphorylation, and Akt Activation

  2015cites this paper
• The Akt1/IL-6/STAT3 pathway regulates growth of lung tumor initiating cells

  2015cites this paper
• The Experimental Study on the Treatment of Cytokine-Induced Killer Cells Combined with EGFR Monoclonal Antibody Against Gastric Cancer

  2014cites this paper
• Abnormal activation of the EGFR signaling pathway mediates the downregulation of miR‑145 through the ERK1/2 in non-small cell lung cancer.

  2014cites this paper
• Restoration of miR-7 expression suppresses the growth of Lewis lung cancer cells by modulating epidermal growth factor receptor signaling.

  2014cites this paper
• TPCA-1 Is a Direct Dual Inhibitor of STAT3 and NF-κB and Regresses Mutant EGFR-Associated Human Non–Small Cell Lung Cancers

  2014cites this paper
• Role of STAT3 in lung cancer.

  2014cites this paper
• Survivin and pAkt as potential prognostic markers in squamous cell carcinoma of the head and neck.

  2014cites this paper
• Phosphorylated Akt expression is a prognostic marker in early-stage non-small cell lung cancer

  2013cites this paper
• Loss of p53 Attenuates the Contribution of IL-6 Deletion on Suppressed Tumor Progression and Extended Survival in Kras-Driven Murine Lung Cancer

  2013cites this paper
• Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non‐small‐cell lung cancer

  2013cites this paper
• Cytotoxicity of cytokine-induced killer cells targeted by a bispecific antibody to gastric cancer cells

  2013cites this paper
• Reconstruction of an Integrated Genome-Scale Co-Expression Network Reveals Key Modules Involved in Lung Adenocarcinoma

  2013cites this paper
• p14ARF inhibits the growth of lung adenocarcinoma cells harbouring an EGFR L858R mutation by activating a STAT3-dependent pro-apoptotic signalling pathway

  2013cites this paper
• Resveratrol induces Sirt1-dependent apoptosis in 3T3-L1 preadipocytes by activating AMPK and suppressing AKT activity and survivin expression.

  2012cites this paper
• Modeling of Tumor Progression in NSCLC and Intrinsic Resistance to TKI in Loss of PTEN Expression

  2012cites this paper
• Charakterisierung von in vivo Modellen des humanen nicht-kleinzelligen Lungenkarzinoms zur Therapieoptimierung

  2012cites this paper
• STAT3 Is Activated by JAK2 Independent of Key Oncogenic Driver Mutations in Non-Small Cell Lung Carcinoma

  2012cites this paper
• Dysregulation of janus kinases and signal transducers and activators of transcription in cancer.

  2011cites this paper
• Correlation of Activated STAT3 Expression with Clinicopathologic Features in Lung Adenocarcinoma and Squamous Cell Carcinoma

  2011cites this paper
• Clinical Significance of Pretreatment C-Reactive Protein in Patients with Advanced Nonsquamous, Non-Small Cell Lung Cancer Who Received Gefitinib

  2011cites this paper
• CK2 Inhibitors Enhance the Radiosensitivity of Human Non-Small Cell Lung Cancer Cells Through Inhibition of Stat3 Activation

  2011cites this paper
• Increased trefoil factor 3 levels in the serum of patients with three major histological subtypes of lung cancer

  2011cites this paper
• Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancer

  2011cites this paper
• Multifaceted Intervention by the Hsp90 Inhibitor Ganetespib (STA-9090) in Cancer Cells with Activated JAK/STAT Signaling

  2011cites this paper
• Imbalanced expression of mitogen-activated protein kinase phosphatase-1 and phosphorylated extracellular signal-regulated kinases in lung squamous cell carcinoma

  2011cites this paper
• Kinase-driven pathways of EGFR in lung carcinomas: perspectives on targeting therapy.

  2011cites this paper
• Induction of the Mitochondria Apoptosis Pathway by Phytohemagglutinin Erythroagglutinating in Human Lung Cancer Cells

  2011cites this paper
• Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy

  2011cites this paper
• Akt signalling in health and disease.

  2011cites this paper
• Elucidating the mechanism of regulation of transforming growth factor β Type II receptor expression in human lung cancer cell lines.

  2011cites this paper
• Contrôle de la signalisation oncogénique du mutant L858R de l'EGFR par la protéine suppresseur de tumeur p14ARF dans les adénocarcinomes pulmonaires

  2011cites this paper
• Contrôle de la signalisation oncogénique du mutant L858R de l'EGFR par la protéine

  2011cites this paper
• c-Cbl、Cbl-b和EGFR在非小细胞肺癌中的表达及其预后价值

  2011cites this paper
• Regulation of cytokine-induced prostanoid and nitric oxide synthesis by extracellular signal–regulated kinase 1/2 in lung epithelial cells

  2010cites this paper
• PED interacts with Rac1 and regulates cell migration/invasion processes in human non‐small cell lung cancer cells

  2010cites this paper
• Increased expression of Akt2 and activity of PI3K and cell proliferation with the ascending of tumor grade of human gliomas.

  2010cites this paper
• Prognostic and predictive factors in resected non-small-cell lung cancer.

  2010cites this paper
• Characterization of the small molecule kinase inhibitor SU11248 (Sunitinib/ SUTENT) in vitro and in vivo

  2010cites this paper
• Clinical impact of phosphorylated signal transducer and activator of transcription 3, epidermal growth factor receptor, p53, and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray

  2010cites this paper
• Overexpression of Phospho-eIF4E Is Associated with Survival through AKT Pathway in Non–Small Cell Lung Cancer

  2009cites this paper
• THE PHARMACOGENOMICS OF EGFR-DEPENDENT NSCLC: PREDICTING AND ENHANCING RESPONSE TO TARGETED EGFR THERAPY

  2009cites this paper
• Differential ErbB receptor expression and intracellular signaling activity in lung adenocarcinomas and squamous cell carcinomas.

  2009cites this paper
• Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma cells.

  2009cites this paper
• High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886)

  2009cites this paper
• Expression of epidermal growth factor receptor and vascular endothelial growth factor in non-small cell lung cancer and its clinical significance: Expression of epidermal growth factor receptor and vascular endothelial growth factor in non-small cell lung cancer and its clinical significance

  2008cites this paper
• Mechanisms of Disease: signal transduction in lung carcinogenesis—a comparison of smokers and never-smokers

  2008cites this paper
• Southwest Oncology Group Phase II Trial (S0341) of Erlotinib (OSI-774) in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2

  2008cites this paper
• E-cadherin expression and epidermal growth factor receptor mutation status predict outcome in non-small cell lung cancer patients treated with gefitinib.

  2008cites this paper
• Regression of Drug-Resistant Lung Cancer by the Combination of Rosiglitazone and Carboplatin

  2008cites this paper
• Correlation between EGFR gene mutation pattern and Akt phosphorylation in pulmonary adenocarcinomas

  2007cites this paper
• Combined oligonucleotide microarray-bioinformatics and constructed membrane arrays to analyze the biological pathways in the carcinogenesis of human lung adenocarcinoma.

  2007cites this paper
• Epidermal growth factor receptor distribution in pericoronal follicles: relationship with the origin of odontogenic cysts and tumors.

  2007cites this paper
• Activation state EGFR and STAT-3 as prognostic markers in resected non-small cell lung cancer.

  2007cites this paper
• Targeting mTOR signaling in lung cancer.

  2007cites this paper
• Activation of the signal transducers and activators of the transcription 3 pathway in alveolar epithelial cells induces inflammation and adenocarcinomas in mouse lung.

  2007cites this paper
• Role of tight junctions in cell proliferation and cancer.

  2007cites this paper
• Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas.

  2007cites this paper
• Characterization of cell-type specific profiles in tissues and isolated cells from squamous cell carcinomas of the lung.

  2006cites this paper
• Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors.

  2006cites this paper
• Differential expression of STAT5 and Bcl-xL, and high expression of Neu and STAT3 in non-small-cell lung carcinoma.

  2006cites this paper
• Phosphorylated Extracellular Signal-regulated Kinases Are Significantly Increased in Malignant Mesothelioma

  2006cites this paper
• Genomic Approaches to Lung Cancer

  2006cites this paper